This is an unofficial version.
|Search this Act
S.M. 2011, c. 4
Bill 14, 5th Session, 39th Legislature
The Prescription Drugs Cost Assistance Amendment Act (Prescription Drug Monitoring and Miscellaneous Amendments)
(Assented to June 16, 2011)
HER MAJESTY, by and with the advice and consent of the Legislative Assembly of Manitoba, enacts as follows:
Section 1 is amended
(a) by adding the following definition:
"monitored drug" means a specified drug, or a class of specified drugs, designated in the regulations as a monitored drug; (« médicament contrôlé »)
(b) by replacing the definition "specified drug" with the following:
"specified drug" means a drug or other item
(a) that is specified in the regulations, or
The following is added after subsection 2(2):
A benefit in respect of a drug or other item described in clause (b) of the definition "specified drug" must not be paid to or on behalf of a person unless an approval for the drug or other item has been specifically granted to the person under a regulation made under clause 9(1.1)(a.1).
The following is added after section 3:
The minister may establish one or more advisory committees to provide the minister with advice and recommendations respecting the administration or enforcement of this Act and its regulations.
Subsection 9(1.1) is amended by adding the following after clause (a):
(a.1) respecting the procedure by which an application may be made, by or on behalf of an eligible person, to have a drug or other item not specified in a regulation made under clause (a) approved as a drug or other item for which benefits may be paid, the procedure for considering an application, and the grounds upon which an application may be approved;
(a.2) designating a specified drug, or a class of specified drugs, as a monitored drug, including, without limitation, designating a specified drug that is a controlled substance as defined in the Controlled Drugs and Substances Act (Canada) as a monitored drug;
The following is added after clause 10(5)(f):
The following is added after clause 10(5)(g):
(g.1) subject to subsection (5.1), to a regulatory body governing a profession that has authority to prescribe or dispense a monitored drug, for the purpose of the regulatory body monitoring or reviewing
(i) the patterns of its members' prescribing or dispensing practices relating to monitored drugs, or
(ii) the utilization of monitored drugs by patients or clients of its members,
Clause 10(5)(h) is replaced with the following:
(h) subject to subsection (5.1), to a regulatory body governing a profession mentioned in clause (g), for the purpose of the regulatory body auditing or investigating a member, including an investigation for disciplinary purposes, in relation to inappropriate or fraudulent prescribing or dispensing, or abuse or misuse, of a monitored drug or other specified drug;
The following is added after subsection 10(5):
The disclosure of personal health information, as defined in The Personal Health Information Act, about a patient or client, or of other information that could reasonably be expected to identify a patient or client, is not authorized
(a) under clause (5)(f.1) or (g.1); or
The following is added after section 10:
If the minister believes, based on advice from an advisory committee established under section 3.1, that the prescribing or dispensing practices of a member of a profession that has authority to prescribe or dispense a drug or other item may be inappropriate or not in accordance with generally accepted prescribing or dispensing practices, the minister may refer the matter, or make a complaint about the matter, to the regulatory body governing the person's profession.
The following is added after section 15:
The minister may enter into agreements with any person or group of persons, or with the government of any jurisdiction, as the minister considers necessary for the purposes of this Act.
This Act comes into force on a day to be fixed by proclamation.